Key milestone achieved in Flavocide production

Bio-Gene Technology Limited (ASX:BGT) and Rallis India Limited have successfully completed the pilot-scale production of pre-commercial quantities of Flavocide, a nature-identical insecticide. Rallis, a subsidiary of Tata Chemicals Limited, demonstrated the capability to produce Flavocide at a consistent quality and yield, positioning Bio-Gene for future supply to its commercial licensees.

Executive commentary on successful pilot-scale production

We are extremely pleased to have achieved the successful pilot-scale production of multiple batches of Flavocide with high yield and consistency. Reaching this important milestone significantly reduces the technical risk associated with the production of Flavocide in commercial quantities. We are now well positioned to supply larger quantities to our commercial partners in the future. Rallis has a global reputation of being a trusted solutions provider for the manufacture, development, and distribution of agrochemical active ingredients. By engaging with Rallis, we have been able to access high-quality manufacturing facilities and expertise, with the capacity to produce commercial scale quantities of Flavocide and to adjust production volumes in response to market demands. It has been a real pleasure for our team to work closely with Rallis on this program. I congratulate all those involved from Bio-Gene and Rallis for achieving this important milestone.

Summary of Flavocide production milestone and outlook

Bio-Gene Technology Limited and Rallis India Limited have successfully achieved the pilot-scale production of pre-commercial quantities of Flavocide, marking a significant milestone in the development of this nature-identical insecticide. The successful production validates the production process at a larger scale and establishes proven standard operating procedures for future large-scale manufacturing of Flavocide. This positions Bio-Gene to move forward with the remaining studies to support its application for regulatory approval of Flavocide for commercial use. The company's business model involves entering into licensing arrangements with commercial partners internationally to formulate and develop insecticidal products containing Flavocide, with an outlook to receive up-front and milestone payments as well as royalties from its commercial partners upon sale of these new products. The partnership with Rallis provides Bio-Gene access to high-quality manufacturing facilities and expertise, enhancing its capacity to meet future market demands for Flavocide-based solutions.